Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 20/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2811223 | 0.99 | REN (0.64) | REN | |
| Hydrochloric Acid SCHEMBL2811222 | 0.99 | REN (0.64) | REN | |
| SCHEMBL13126342 | 0.94 | REN (0.70) | REN | |
| SCHEMBL8294039 | 0.93 | REN (0.66) | REN | |
| Hydrochloric Acid SCHEMBL2807295 | 0.93 | REN (0.69) | REN | |
| Hydrochloric Acid SCHEMBL2807299 | 0.93 | REN (0.69) | REN | |
| Hydrochloric Acid SCHEMBL2807594 | 0.92 | REN (0.65) | REN | |
| Hydrochloric Acid SCHEMBL2807591 | 0.92 | REN (0.65) | REN | |
| SCHEMBL13126345 | 0.91 | REN (0.64) | REN | |
| Hydrochloric Acid SCHEMBL2808480 | 0.90 | REN (0.63) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362040-B2 | 4-phenylpiperidine derivatives as renin inhibitors | NOVARTIS AG (CH) | 2013-01-29 | — | — | US | disclosed |
| US-8362040-B2 | 4-phenylpiperidine derivatives as renin inhibitors | NOVARTIS AG (CH) | 2013-01-29 | — | — | US | disclosed |
| US-20100240679-A1 | 4-Phenylpiperidine Derivatives as Renin Inhibitors | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| US-20100240679-A1 | 4-Phenylpiperidine Derivatives as Renin Inhibitors | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| US-7754727-B2 | 4-phenylpiperidine derivatives as renin inhibitors | NOVARTIS AG (CH) | 2010-07-13 | — | — | US | disclosed |
| US-7754727-B2 | 4-phenylpiperidine derivatives as renin inhibitors | NOVARTIS AG (CH) | 2010-07-13 | — | — | US | disclosed |
| EP-1689712-B1 | 4-PHENYLPIPERIDINE DERIVATIVES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2009-08-19 | — | — | EP | disclosed |
| US-20080269255-A1 | 4-Phenylpiperidine Derivatives as Renin Inhibitors | NOVARTIS AG (CH) | 2008-10-30 | — | — | US | disclosed |
| US-20080269255-A1 | 4-Phenylpiperidine Derivatives as Renin Inhibitors | NOVARTIS AG (CH) | 2008-10-30 | — | — | US | disclosed |
| US-20070078164-A1 | 4-Phenylpiperidine derivatives as renin inhibitors | SEDRANI RICHARD | 2007-04-05 | — | — | US | disclosed |
| US-20070078164-A1 | 4-Phenylpiperidine derivatives as renin inhibitors | SEDRANI RICHARD | 2007-04-05 | — | — | US | disclosed |
| WO-2005051911-A1 | 4-PHENYLPIPERIDINE DERIVATIVES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269255-A1 | 4-Phenylpiperidine Derivatives as Renin Inhibitors | REN, AGTR1, ACE | REN 1/4885 |
| US-20100240679-A1 | 4-Phenylpiperidine Derivatives as Renin Inhibitors | REN, AGTR1, ACE | REN 1/4885 |
| US-20070078164-A1 | 4-Phenylpiperidine derivatives as renin inhibitors | REN, AGTR1, ACE | REN 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.